Aim COVID-19 pandemic changed the priorities in medical field. Many elective surgeries for renal cell cancers (RCC) have been postponed. In this study, we aimed to examine the effects of the COVID-19 pandemic on the surgical treatment of RCC in Turkey. Methods 457 patients that underwent surgery for kidney tumor in the 2-year period between March 1, 2019 and February 28, 2021 in 9 centers in Turkey were analyzed retrospectively. Results The number of surgical treatments for RCC during the COVID-19 pandemic has decreased significantly compared to the same period before COVID-19. No significant differences were found between the two periods in terms of admission symptoms (p=0.32). However, while the rate of application due to hematuria was 6.1% in the pre-COVID-19 period, it was 13.1% during the COVID-19 period. Despite not being significant, this difference was still proportional. Two study periods differed significantly in terms of the rate of metastatic RCC detected in preoperative imaging (13.1% vs 6.1%, during COVID-19 and pre-COVID-19, respectively) (p=0.01). Moreover, the study periods differed significantly in terms of time between imaging and operation (55.98±51.02 vs 40.30±34.9 days, during COVID-19 and pre-COVID-19, respectively) (p=0.01). However, there was no significant difference between the two periods in terms of tumor size, type of surgery, and pathological stage (p>0.05). Conclusion There was a significant decrease in the number of RCC-related surgeries over 1-year period during the pandemic. However, the rate of surgery for metastatic disease increased. Covid-19 is a pandemic that continues to affect the whole world. Oncological diseases are negative affected in this process in terms of early diagnosis and treatment.

Objective: The objective of this study was to evaluate the effects of Metabolic Syndrome (MetS) and MetS components on tumor size, Fuhrman grade and pathological T stage in renal cell carcinoma (RCC). Materials and Methods: The data of 151 patients who were operated for RCC between January 2010 and April 2018 were retrospectively reviewed according to the he National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), and the effects of MetS and its components on tumor size, Fuhrman grade and pathological T stage were comparatively investigated. Results: Of the 151 patients operated for RCC in our clinic, 27.2% had MS, 29.1% had diabetes mellitus (DM), 41% had hypertension (HT), 68.3% had low high-density lipoprotein (HDL), 41% had elevated triglyceride (TGL) elevation, and 27.2% had obesity. It was found that the size of the tumor was statistically significantly increased in the presence of the metabolic criteria examined. There was a statistically significant increase in the Fuhrman grade of the patients with MetS, DM, low HDL, high TGL and obesity. In the presence of clinical conditions such as HT, low HDL and high TGL, there was a statistically significant increase in the pathological T stage. Conclusion: In patients undergoing surgery for RCC, MetS and its components had a statistically significant correlation with tumor size, Fuhrman grade, and pathological stage. If our results are supported by further studies, the correlation between MetS and RCC could be revealed more clearly.